Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leucovorin calcium ANDA suitability petitions

Executive Summary

Burroughs-Wellcome asked FDA for permission on file an ANDA for a 100 mg sterile powder version of Lederle's 50 mg injectable. B-W already markets Wellcovorin liquid and tablets. Besides proposing a higher strength, B-W proposed to deviate from Lederle's labeling by borrowing from the Wellcovorin tablet labeling the clinical pharmacology, indications and usage, contraindications, warnings, precautions, overdosage, and dosage and administration sections. Wellcovorin labeling "contains the most up-to-date prescribing information [and] a better presentation of content and format," the firm said. In addition, Quad Pharmaceuticals asked to submit an ANDA for a 10 mg/ml, 5 ml sterile fill solution, and David Bull Labs, Ltd. proposed an ANDA for a 10 mg/ml concentration.

You may also be interested in...

'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips

Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.

Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal

Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts